本页面由Tiger Trade Technology Pte. Ltd.提供服务

Redhill Biopharma Ltd

1.16
-0.0600-4.92%
成交量:3.32万
成交额:4.00万
市值:386.27万
市盈率:-0.19
高:1.24
开:1.22
低:1.16
收:1.22
52周最高:7.30
52周最低:1.01
股本:332.99万
流通股本:307.58万
量比:0.43
换手率:1.08%
股息:- -
股息率:- -
每股收益(TTM):-6.0249
每股收益(LYR):-6.7096
净资产收益率:-1708.61%
总资产收益率:-25.32%
市净率:-0.88
市盈率(LYR):-0.17

数据加载中...

2025/06/30

SEC问询函

Form CORRESP - Correspondence
2025/06/25

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2025/04/10

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/03/26

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/11/14

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/08/16

SEC问询函

Form CORRESP - Correspondence
2024/06/20

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/04/08

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/02/15

SEC问询函

Form CORRESP - Correspondence
2024/02/09

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2024/02/02

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/01

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/01/08

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/10/26

SEC问询函

Form CORRESP - Correspondence
2023/08/10

SEC问询函

Form CORRESP - Correspondence
2023/06/29

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/04/28

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/01/13

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/06/27

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2022/03/17

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]